Innovative Test Enhances Quality Control in Allergy Treatments
A novel immunoassay developed by the Paul Ehrlich Institute allows precise measurement of allergoids in allergy medicines, improving quality control and standardization of allergy immunotherapy products.
A multidisciplinary team from the Allergology and Veterinary Medicine Divisions at the Paul Ehrlich Institute has developed a groundbreaking laboratory assay that allows for the precise quantification of adjuvanted allergoids within finished allergy medicinal products. Previously, assessing the content of these complex formulations was challenging due to their intricate structures, which contain both allergen-modifying compounds (allergoids) and adjuvants, restricting analysis to intermediary production stages. The newly introduced testing method marks a significant breakthrough in the quality assurance of allergy immunotherapy (AIT) medications.
Allergy immunotherapy involves using sensitized allergens to train the immune system towards tolerance, with allergoids being chemically modified allergens designed for this purpose. Accurate dosing and proven efficacy depend heavily on knowing the exact allergoid concentration, yet until now, this measurement in final pharmaceutical formulations was not feasible. The novel immunoassay employs highly specific antibodies in an enzyme-linked detection system, enabling accurate, reliable detection of allergoids directly in medicinal products. This method can effectively eliminate the need for animal testing and enhances the standardization and quality control processes.
The research, published in the journal "Allergy," demonstrates that this assay can consistently measure allergen content in grass pollen allergoids, which are common components in allergy therapy. The project was led by Dr. Frank Führer from the Paul Ehrlich Institute, emphasizing the importance of this advancement for regulatory oversight and manufacturing quality assurance. The implementation of such precise testing protocols promises to improve the consistency, safety, and efficacy of allergy treatments, benefiting both manufacturers and patients.
This development reinforces the Paul Ehrlich Institute's role in ensuring the safety and quality of allergy immunotherapies, responding to regulatory requirements by providing a sophisticated tool for batch testing and standardization. Source: https://medicalxpress.com/news/2025-06-quality-allergy-therapeutics.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advanced Monitoring During Heart Surgery Shows No Reduction in Complication Risks
A large-scale study finds that high-tech tissue oxygen monitoring during heart surgery does not reduce the risk of serious post-operative complications, guiding future innovations in surgical care.
Study Finds No Antidepressant Benefits of Cholesterol-Lowering Medications
A recent large-scale study concludes that cholesterol-lowering drugs, such as statins, do not have an antidepressant effect, reaffirming their primary role in cardiovascular health management.
The Placenta's Role as a Serotonin Regulator: Implications for Fetal Development
New research from Yale uncovers the placenta's vital role as a 'serotonin shield,' regulating maternal serotonin transfer and influencing fetal growth and brain development during pregnancy.
How Systemic Inflammation Links Autoimmune Diseases to Mental Health Challenges
A large UK study reveals that systemic inflammation linked to autoimmune diseases significantly increases the risk of mental health disorders, especially among women. Early screening and intervention are recommended.